Idiopathic Pulmonary Fibrosis Market Size is Expected to Reach USD 9.23 Billion by 2033 ...
The global idiopathic pulmonary fibrosis market size was valued at USD 4.54 billion in 2024 and is projected to reach from ...
BioWorld1 天
LMO7 as therapeutic target to block profibrotic fibroblast polarization in IPF
Researchers from Shanghai Jiao Tong University and affiliated organizations have published their findings from studies that aimed to investigate the pathogenesis of idiopathic pulmonary fibrosis (IPF) ...
Stockhead on MSN6 天
The ASX players bringing new hope to IPF sufferers
Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to ...
HealthDay on MSN7 天
About 1 in 5 Idiopathic Pulmonary Fibrosis Deaths May Be Due to Occupational Exposures
According to a recent study, roughly one in five of idiopathic pulmonary fibrosis deaths might be related to occupational exposures.
Managed Healthcare Executive1 天
TGen Study Leverages Advanced Genomics to Map Lung Tissue Changes
Significant alterations in the structure and cellular composition of the distal lung are a defining characteristic of ...
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials
Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...
GRI Bio Participates in a Virtual Investor CEO Connect Segment
Access the CEO Connect segment hereLA JOLLA, CA, March 18, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a ...
heraldsun.com.au7 天
The ASX players bringing new hope to IPF sufferers
Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to sufferers. Characterised by the thickening and scarring of lung tissue ...